Exploratory biomarker insights to guide your decision-making from discovery to the clinic

Flexible, fit-for-purpose biomarker support to propel your drug development.

  • Accelerate your progress with a translational biomarker strategy 

  • Access collaborative support with fit-for-purpose assay development and validation

  • Identify and access cutting-edge technologies and expertise


Translational biomarkers can play a critical role in helping you quickly assess biomarker feasibility to better understand how it can be utilized in a clinical environment.  分析定性不可一概而论。 You need a flexible approach that considers your phase of development and desired outcomes to provide the best support for the intended use of your data.

Exploratory biomarkers, while not guided by specific regulations, still utilize robust quality principles, expertise and process to deliver high-quality and reliable data. A trusted partner who has familiarity with CAP/ CLIA and GxP environments can streamline your transition and retain critical insights about your assay and goals.


Since 2009, the Translational Biomarker Solutions (TBS) team has been supporting assay development and validation needs in an exploratory - but, principled - environment. Expertise in cellular analysis and immunoassays can help you develop your strategy from concept to implementation to meet your critical goals for exploratory biomarkers.  

Specialized Support


  • Ultrasensitive
  • Custom-immunogenicity assays
  • Low-sample volume with improved detection
  • Multiplexed and specialized platform assays 
  • Electrochemiluminescence
  • Microfluidics-based ELISA
  • Kit-based immune assays
  • Immunoassay autoanalyzers 

Cellular-based Analysis

  • High-parameter immunophenotyping of blood, PBMC and tissues
  • In vitro Pharmacology
  • Immunotoxicology for cytokine release
  • Cellular Immunology
  • Cell-Based Assays (including ADCCs, CDCs, Proliferation, Apoptosis and viability, etc.)

Flexible and fit-for-purpose biomarker testing solutions

From initial feasibility and development to advanced validation, testing and production, we deliver insights to drive your decision making. Our team provides unique solutions for historic (banked) samples, difficult matrix types, or complex assay development in a flexible environment that provides robust exploration to guide new paths forward in biomarker discovery. As your clinical biomarker needs evolve, the TBS team can help you transition seamlessly into a CAP/CLIA or GxP environment for qualification, method validation and implementation.

Extended reach with access to the optimal technologies

Comprehensive knowledge of assays spanning ultrasensitive and multiplexed, kit-based and custom-built, low-sample volume and cell-based, gives you an experienced partner with access to a toolbox of diverse platforms. Together, we can support your biomarker analysis and advance your discovery through the use of precision technology, such as:

  • Quanterix Simoa
  • Meso Scale Discovery (MSD)
  • Luminex
  • Protein Simple ELLA
  • Gyros
  • ECLIA (Roche e601)
  • Octet
  • Cytoflex (Beckman Coulter 6-color)
  • Miltenyi Automacs Pro
  • Miltenyi Octo Dissociator
  • BD Fortessa X-20 (18-Color)
  • CTL ImmunoSpot

A quality approach to biomarkers in a non-regulated environment

In parallel with Covance's regulated lab work, the TBS team works under a set of standardized quality principles to ensure accuracy and quality for your exploratory objectives of the studies. This system is further verified by both internal and external QA audits, as well as proficiency testing, giving you confidence that the data produced meets the highest standard of quality. 

Working with TBS, you get a set of reliable and reconstructable results that enables informed development decisions and a structured transition to the regulatory environment required to progress to your next milestone. 

Next, meet the team that will work with you to help solve your translational biomarker challenges.

Erica L. Troksa,博士

Erica L. Troksa,博士


Erica L. Troksa博士负责推动转化生物标记物解决方案团队的整体科学绩效和高质量服务的按时交付。她充分利用了自己在生物分析免疫测定研发、优化和执行方面的16多年经验 。  Troksa博士已领导开发和验证了适用于多种平台的新型免疫测定方法。

2013年3月加入科文斯之前,她曾担任EMD Millipore现场科学家,为研究科学家提供多重免疫测定、流式细胞术、蛋白质定量和其他技术应用方面的技巧培训。 Troksa博士以芝加哥伊利诺伊大学杰出研究生的身份荣获了Klaus R. Unna奖。她是有关多个主题的多篇同行评审期刊文章的作者或合著者。

Paul C. Trampont,博士

Paul C. Trampont,博士


Paul C. Trampont博士领导一支科学家和技术人员团队,负责开发基于细胞的测定法以支持药物研发。他于2014年12月加入科文斯,在人体免疫学和肿瘤学研究领域拥有20多年专业经验。在加入科文斯之前,他曾在弗吉尼亚大学医学院血液肿瘤系担任助理教授。


Bhaskarjyoti Sarmah,博士

Bhaskarjyoti Sarmah,博士


Bhaskarjyoti Sarmah博士领导我们的科学家团队负责开发、验证和执行可溶性生物标志物免疫测定和生物测定。 他在10多年的生物标志物和靶向药物筛选研究工作中积累了丰富经验,涉及多个治疗领域,包括心血管疾病、肾脏疾病、自身免疫/炎性疾病和免疫肿瘤学。

Sarmah博士是超过24篇期刊文章、海报和演示文稿的作者或合著者。2017年1月加入科文斯之前,他曾担任Eli Lilly & Co生物技术药物筛选研究的研究科学家。

Chris W. Stamatkin,博士

Chris W. Stamatkin,博士


Chris W. Stamatkin博士担任免疫测定法和特殊化学的研究员和负责人。他领导一支科学家和技术人员团队,负责开发基于细胞的测定法以支持药物研发。  他于2017年11月加入科文斯,在实验室研究和药物研发方面拥有14多年经验。

Stamatkin博士此前曾在印第安纳大学医学院血液学/肿瘤学系担任助理研究教授,并在印第安纳大学西蒙癌症中心担任Therapeutic Validation Core和Angio BioCore助理主任。Stamatkin是许多同行评审的科学期刊文章、摘要和演示文稿的作者及合著者,经常在行业会议上发表演讲。

Katherine (Katie) A. Masterson

Katherine (Katie) A. Masterson